In a comparison of two erythropoiesis-stimulating agents, drug costs were found to be lower for epoetin alfa than for darbepoetin alfa.
You are here
P&T® Journal contents for December 2007
Erythropoietic Therapy: Dosing Patterns and Calculated Cost Assessment for Pre-dialysis Chronic Kidney Disease Patients In a Managed Care Setting
Analysis and Opinion
Although far from perfect, the FDA Amendments Act gives the FDA more funds and authority, for example, in overseeing drug distribution and in forcing manufacturers to provide drug guides and to perform post-approval safety trials.
There won’t be any juicy industry gossip or corporate intrigue, but Johnson & Johnson and GlaxoSmithKline hope that their new blogs will at least set the record straight about their companies and products.
Topics include galiximab, bendamustine, and rituximab for hematological malignancies; pazopanib for renal cell cancer; trastuzumab and lapatinib for breast cancer; sorafenib/temozomide for melanoma; and IRX-2 for head and neck cancer
Presentations cover advances in therapies for breast, prostate, and renal cancers and melanoma; adalimumab for patients with Crohn’s disease and fistula; and infliximab for the treatment of ulcerative colitis and colectomy.
Notice how we haven’t aged a bit in five years!